NWRD09 for HPV-16 related cervical high-grade changes
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called NWRD09 for women with high-grade cervical cell changes (CIN 2/3) caused by HPV type 16. The goal is to see if the drug can help clear these abnormal cells without needing surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 65 years old.
- You have tested positive for HPV type 16 and have a biopsy showing high-grade cervical changes (CIN 2 or 3).
- You are not pregnant, breastfeeding, or planning to get pregnant during the study.
- You have not had any previous cancer of the cervix (including adenocarcinoma) or invasive cancer.
- You are not taking medications that suppress the immune system (like steroids, cyclosporine, or methotrexate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NWRD09 for women with a high-grade precancerous cervical condition caused by HPV type 16. If you qualify, you would receive the study drug and be monitored to see if it can help clear the abnormal cells.
This study tests a new treatment (NWRD08) for women with high-grade cervical changes (CIN 2/3) caused by HPV types 16 or 18. It aims to see if the treatment can help clear the abnormal cells and prevent them from becoming cancer.
This trial tests an experimental treatment called NWRD09 for women who have had a persistent HPV 16 infection for at least 12 months. The goal is to see if it can clear the virus and prevent cervical changes.
This trial tests a new drug (NWRD09) for people who have had HPV type 16 infection in the anal area for over a year. It aims to see if the drug can help clear the virus without causing serious side effects.
This trial tests an experimental shot, BBM-C101, for women with a specific type of cervical pre-cancer caused by HPV types 16 or 18. The goal is to see if the shot is safe and can help the body fight the infection, possibly eliminating the abnormal cells.
This trial tests a new medicine called NWRD09 for people with HPV-16 related cervical cell changes (HSIL) or advanced cervical cancer. The goal is to see if it can help treat these conditions.
Hear when a new High-grade Squamous Intraepithelial Lesion (HSIL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.